Back to Authors

Dorr, Andrew

A5011633842

Mayo Clinic

Independent Consultant for S*BIO Pte Ltd., Singapore;

Citations 1

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655

10.1182/blood-2013-02-484832 | PMID 25762180

Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.